Natural Selections

Seven wonder drugs that do grow on trees.

Illustration: Bettmann/Corbis

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.


As much as three-quarters of the drugs approved to treat infectious disease and cancer over the past 25 years originated with chemicals or compounds first found in nature. Which means that last acre of rainforest or ocean floor might contain ever more promising cures. A few notable pharmaceuticals that got their start outside the laboratory:

ASPIRIN In the fifth century BC, Hippocrates noted willow bark’s ability to fight fevers and pain. A chemical found in the bark became the key ingredient of aspirin, patented in 1900.

QUININE Indigenous Peruvians used the bark of the cinchona tree to cure fevers. European scientists isolated its antimalarial ingredient in the early 19th century.

LOVASTATIN This chemical, found in the fungus Aspergillus terreus and oyster mushrooms, reduces LDL “bad” cholesterol. In 1987 it became the first FDA-approved statin.

CALANOLIDE A In the late 1980s, a rare tree from Borneo was found to have antiretroviral properties. Still in trials, the resulting drug has shown promise in combating HIV.

TAXOL Tumor-fighting compound derived from the bark of the Pacific yew, introduced as a cancer drug in 1993. It’s since been found in some mushrooms and mycelia.

YONDELIS A cancer drug modeled after an agent discovered in a Caribbean sea squirt. Currently available only in the EU.

PRIALT In 2004, Elan Pharmaceuticals unveiled this drug for treating chronic pain, made from synthetic sea-snail venom. The drug’s logo is a snail shell.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate